LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Pipeline Neurana Pharmaceuticals is advancing a novel CNS-focused treatment, tolperisone, which has demonstrated safety and efficacy outside the US, indicating potential for expansion into new markets and licensing opportunities.

Recent Clinical Setback The company recently launched Phase 3 RESUME-1 trial which did not meet primary or secondary endpoints, highlighting an area for targeted support in clinical development and potential opportunities to collaborate on study optimization or alternative indications.

Strategic Funding With a significant $60 million raised in Series A funding from top biotech investors, Neurana is positioned to accelerate clinical and commercial efforts, suggesting opportunities for sales partnerships as new markets and products are developed.

Leadership Experience Recent hires including a President/CEO and Chief Medical Officer with pharmaceutical biotech backgrounds suggest a company poised for growth and open to strategic alliances in clinical development, commercialization, or distribution.

Niche Market Focus Specializing in neuromuscular conditions with a focus on acute muscle spasms, Neurana offers tailored solutions targeting a specific medical segment with limited current competition, providing opportunities for joint ventures or specialty distribution agreements.

Neurana Pharmaceuticals Tech Stack

Neurana Pharmaceuticals uses 8 technology products and services including WordPress, Webpack, Twemoji, and more. Explore Neurana Pharmaceuticals's tech stack below.

  • WordPress
    Content Management System
  • Webpack
    Development
  • Twemoji
    Font Scripts
  • TweenMax
    Javascript Frameworks
  • Zepto
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines

Media & News

Neurana Pharmaceuticals's Email Address Formats

Neurana Pharmaceuticals uses at least 1 format(s):
Neurana Pharmaceuticals Email FormatsExamplePercentage
FLast@neuranapharma.comJDoe@neuranapharma.com
100%

Frequently Asked Questions

Where is Neurana Pharmaceuticals's headquarters located?

Minus sign iconPlus sign iconNeurana Pharmaceuticals's main headquarters is located at 3525 Del Mar Heights Road Suite 609 San Diego, California 92130 United States. The company has employees across 2 continents, including North AmericaAsia.

What is Neurana Pharmaceuticals's phone number?

Minus sign iconPlus sign icon You can contact Neurana Pharmaceuticals's main corporate office by phone at
+1-858-756-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Neurana Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign iconNeurana Pharmaceuticals's official website is neuranapharma.com and has social profiles on LinkedIn.

What is Neurana Pharmaceuticals's SIC code NAICS code?

Minus sign iconPlus sign iconNeurana Pharmaceuticals's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Neurana Pharmaceuticals have currently?

Minus sign iconPlus sign iconAs of February 2026, Neurana Pharmaceuticals has approximately 11 employees across 2 continents, including North AmericaAsia. Key team members include Senior Vice President And Chief Financial Officer: K. S.Director Corporate Development: J. H.: S. B.. Explore Neurana Pharmaceuticals's employee directory with LeadIQ.

What industry does Neurana Pharmaceuticals belong to?

Minus sign iconPlus sign iconNeurana Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Neurana Pharmaceuticals use?

Minus sign iconPlus sign iconNeurana Pharmaceuticals's tech stack includes WordPressWebpackTwemojiTweenMaxZeptojQueryPHPYoast SEO.

What is Neurana Pharmaceuticals's email format?

Minus sign iconPlus sign iconNeurana Pharmaceuticals's email format typically follows the pattern of FLast@neuranapharma.com. Find more Neurana Pharmaceuticals email formats with LeadIQ.

How much funding has Neurana Pharmaceuticals raised to date?

Minus sign iconPlus sign icon As of February 2026, Neurana Pharmaceuticals has raised $60M in funding. The last funding round occurred on May 08, 2018 for $60M.

When was Neurana Pharmaceuticals founded?

Minus sign iconPlus sign iconNeurana Pharmaceuticals was founded in 2013.

Neurana Pharmaceuticals

Biotechnology ResearchCalifornia, United States11-50 Employees

Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms.  The Company was founded in 2013 to focus on central nervous system (CNS) diseases and disorders. 

Neurana's first drug candidate is tolperisone, which has been shown to be an effective treatment for muscle spasms and spasticity and is commercialized in markets outside of the United States. Clinical studies and commercial usage have shown that tolperisone is safe and efficacious, and that the drug is non-sedating and non-addictive.

In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and included participation from New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital and MagnaSci Ventures.

Section iconCompany Overview

Headquarters
3525 Del Mar Heights Road Suite 609 San Diego, California 92130 United States
Phone number
+1-858-756-****
Website
neuranapharma.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $60M

    Neurana Pharmaceuticals has raised a total of $60M of funding over 1 rounds. Their latest funding round was raised on May 08, 2018 in the amount of $60M.

  • $1M

    Neurana Pharmaceuticals's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $60M

    Neurana Pharmaceuticals has raised a total of $60M of funding over 1 rounds. Their latest funding round was raised on May 08, 2018 in the amount of $60M.

  • $1M

    Neurana Pharmaceuticals's revenue is estimated to be in the range of $1M

Company Leadership

  • Stylized image of a person
    K. S.
    Senior Vice President And Chief Financial Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. H.
    Director Corporate Development
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. B.
    Phone icon
    Mobile Phone

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.